Topoisomerase IIa (topoIIa) is an essential mammalian enzyme that topologically modifies DNA and is required for chromosome segregation during mitosis. Previous research suggests that inhibition of topoII decatenatory activity triggers a G 2 checkpoint response, which delays mitotic entry because of insufficient decatenation of daughter chromatids. Here we examine the effects of both topoIIa and topoIIb on decatenatory activity in cell extracts, DNA damage and decatenation G 2 checkpoint function, and the frequencies of p16 INK4A allele loss and gain. In diploid human fibroblast lines, depletion of topoIIa by small-interfering RNA was associated with severely reduced decatenatory activity, delayed progression from G 2 into mitosis and insensitivity to G 2 arrest induced by the topoII catalytic inhibitor ICRF-193. Furthermore, interphase nuclei of topoIIa-depleted cells showed increased frequencies of losses and gains of the tumor suppressor genetic locus p16 INK4A . This study shows that the topoIIa protein is required for decatenation G 2 checkpoint function, and inactivation of decatenation and the decatenation G 2 checkpoint leads to abnormal chromosome segregation and genomic instability.
Introduction
DNA topoisomerases are evolutionarily conserved nuclear enzymes that have major functions in the cell cycle, including DNA replication, recombination and chromosome segregation (Larsen et al., 1996; Wang, 2002) . The two major families of topoisomerases are differentiated by the type of enzymatic reactions each of them performs. Type-I topoisomerases produce proteinassociated single-strand breaks in DNA and relieve supercoiling tension by free rotation of the cut strand around the intact strand. Type-II topoisomerases produce protein-associated DNA double-strand breaks (DSBs) and are capable of passing an intact DNA duplex through the protein-associated DSB. Thus, only type-II topoisomerases can separate knotted and intertwined DNA molecules. Mammalian species express two topoII isoforms: a and b. Each isoform is encoded by a separate gene located on different human chromosomes and can be distinguished by their mass (Capranico et al., 1992; Austin and Marsh, 1998; Burden and Osheroff, 1998) . The two isoforms share B70% homology at the amino-acid level, and exist as homodimeric enzymatic complexes with similar catalytic activities, although a/b heterodimers have been observed (Biersack et al., 1996; Gromova et al., 1998) .
TopoIIb is non-essential and constitutively expressed, whereas topoIIa is an essential gene maximally expressed in G 2 -and M-phase (Heck et al., 1988; Goswami et al., 1996; Akimitsu et al., 2003) . TopoII activity is required for chromosome condensation, decatenation of intertwined daughter DNA duplexes and centromere resolution (Maeshima et al., 2005; Coelho et al., 2008; Wang et al., 2008) . Catenations between chromatid arms are removed before mitosis, while centromeric catenations persist up to the metaphase/anaphase transition (Diaz-Martinez et al., 2006; Santamaria et al., 2007) .
DNA and topoIIa form a reversible, covalent complex, often referred to as the cleavage complex (Burden and Osheroff, 1998; Cortes et al., 2003) . TopoII-inhibiting drugs interfere with various stages of the catalytic cycle, and are therefore divided into two classes: poisons and catalytic inhibitors. TopoII poisons such as doxorubicin and etoposide stabilize the cleavage complex, which may block DNA replication forks or transcriptional machinery and create DSBs (Xiao et al., 2003) . On proteolysis of the stabilized cleavage complex, the DSB is exposed; thus, these drugs are used clinically to treat cancers that typically overexpress the topoII enzyme (Jarvinen et al., 1996; Mao et al., 2001; Lorusso et al., 2007) .
In contrast, catalytic inhibitors prevent the formation of the cleavage complex by intercalating into DNA and inhibiting topoII binding, or by stabilizing topoII in a closed-clamp conformation after the ligation step of the catalytic cycle (Roca et al., 1994; Sehested and Jensen, 1996) . Therefore, topoII catalytic inhibitors are primarily used in the clinical setting as an adjunct to reduce the cardiotoxicity of topoII poisons (Lyu et al., 2007) . The ability of topoII catalytic inhibitors to protect against the toxicity of topoII poisons implies that poisons and catalytic inhibitors have very different effects on topoII activity, DNA binding and chromatin structure.
Studies using topoII catalytic inhibitors suggest that G 2 cells monitor the catenation state of intertwined sister chromatids following DNA replication and actively delay progression into mitosis pending sufficient chromatid decatenation (Downes et al., 1994; Deming et al., 2001) . A subset of chromatid catenations appear to be organized in the centromere, and these catenations are not separated until the onset of anaphase (Diaz-Martinez et al., 2006) . Thus, the decatenation G 2 checkpoint appears to monitor the sufficiency of decatenation along the chromosomal arms, and not its completion. The expression of an active decatenation G 2 checkpoint was supported by evidence that the G 2 delay in cells with catalytic inhibition of topoII was dependent on BRCA1 expression and could be over-ridden by caffeine (Deming et al., 2001) . BRCA1 could be required to activate topoIIa by ubiquitylation (Lou et al., 2005) . Other studies have implicated ATR, ATM, Plk1, WRN, MDC1 and Chk1 in the decatenation G 2 checkpoint (Deming et al., 2002; Franchitto et al., 2003; Robinson et al., 2007; Luo et al., 2009; Bower et al., 2010) . Although the presence of a decatenation G 2 checkpoint that is independent of DNA damage has been supported by a variety of studies (Doherty et al., 2003; Nakagawa et al., 2004; Damelin et al., 2005) , the concept is still controversial as ICRF-193 has been shown to activate DNA damage signaling in some cancer cell lines (Nakagawa et al., 2004; Park and Avraham, 2006) .
The study described herein utilizes normal human diploid fibroblast (NHDF) lines isolated from three different individuals and depleted of either topoIIa or topoIIb. These data support a distinction between the decatenation and DNA damage-G 2 checkpoints, and suggest that topoIIa has a role in maintaining genomic stability through chromatid decatenation and decatenation G 2 checkpoint signaling.
Results
TopoIIa is required for decatenatory activity As there are two forms of topoII in mammals, it was necessary to determine the individual contribution of each isoform to cellular decatenatory activity. NHDFs were depleted of topoIIa or topoIIb using smallinterfering RNA (siRNA) and assayed 48 h after electroporation. Representative western blots for three NHDF lines are shown (Figure 1a , Supplementary Figure S1a ). Nuclear extracts were prepared and assayed for in vitro decatenatory activity on catenated circular DNA molecules isolated from trypanosome kinetoplasts (kDNA). Incubation of kDNA with NHDF nuclear extracts released free mini-circles and intermediate mobility DNA species that likely represent catenated dimers or trimers, while topoII decatenatory activity was inhibited by the topoII catalytic inhibitor, ). Furthermore, decatenatory activity was severely reduced in nuclear extracts isolated from topoIIa-depleted cells relative to cells that were electroporated with non-targeting control (NTC) siRNA (Figure 1b, Supplementary Figure S1b ). To-poIIb-depleted nuclear extracts displayed similar activity to that of the NTC extracts. Collectively, these results suggest that topoIIa accounts for the majority of decatenatory activity in actively growing NHDFs.
Catalytic inhibition of topoII with ICRF-193 inhibits mitotic entry
Catalytic inhibitors of topoII enzymes are thought to induce a decatenation G 2 checkpoint and prevent entry into mitosis. In order to verify that the decatenation G 2 checkpoint was effective in NHDFs, live-imaging bright-field microscopy was used. Mitotic NHDFs were clearly distinguishable from interphase fibroblasts under bright-field microscopy because of their round morphology, whereas interphase fibroblasts were flat, thin and elongated. Time-lapse images were collected every 2 min and full-length movies can be viewed at our laboratory website (http://top2a.med.unc.edu/jackie/home.html). Representative images at 0, 1, 4 and 12 h after addition of dimethyl sulfoxide (DMSO) or ICRF-193 are shown, with black arrows designating the mitotic cells ( Figure 2 ). NHDFs exposed to DMSO entered and exited mitosis throughout the length of the movie, whereas catalytic inhibition of topoII with 4 mM ICRF-193 allowed mitotic exit, but not mitotic entry. Flowcytometric analysis of cellular DNA content further showed that greater than 50% of fibroblasts were in G 2 phase after 28 h of incubation with ICRF-193 (Supplementary Figure S2 ). These results indicated that mitotic entry was arrested in NHDFs on catalytic inhibition of topoII enzyme.
ICRF-193 does not induce detectable DNA damage in NHDFs
A few studies have detected DNA damage (particularly DSBs) on inhibition of topoII with ICRF-193. In order to verify that catalytic inhibition of topoII with ICRF-193 did not induce a DNA damage response in NHDFs, immunofluorescence and flow cytometric studies were performed to determine the levels of a common DNA damage marker, gH2AX. In Figure 3a , representative images are shown for NHF1-hTERTs treated for 15 min with DMSO, ICRF-193 or etoposide and stained for gH2AX by immunofluorescence. Etoposide-treated NHDFs displayed many gH2AX foci after 15 min, whereas no detectable gH2AX foci were present after ICRF-193 treatment. Flow cytometric studies were performed in parallel to quantify gH2AX positive NHDFs (Figure 3b ). All NHDFs showed an increase in gH2AX positive cells after etoposide treatment, whereas ICRF-193 treatment induced no detectable gH2AX staining above background levels. Similar results have been observed by western immunoblot analysis in lymphoblast and fibroblast cell lines (Bower et al., 2010) . The slight increase in gH2AX staining seen at the 6 h time point was determined to be statistically insignificant by a Student's t-test, and was the result of an idiosyncratic response by the NHF3-hTERT cell line. NHF3-hTERTs also displayed higher background gH2AX staining and hypersensitivity to both ICRF-193 and topoIIa depletion (Zhou Y and Kaufmann WK, unpublished data and Figure 7c ), suggesting that these cells may display higher levels of cellular stress in culture. Overall, these results indicate that ICRF-193 does not induce DSB formation in NHDFs.
TopoIIa depletion ablates the decatenation G 2 checkpoint response, but has no effect on the DNA damage G 2 checkpoint response ICRF-193 inhibits topoII function by holding the enzyme as a closed clamp that is tethered to DNA but incapable of DNA strand passage, thus rendering cells unable to remove DNA catenations (Roca et al., 1994; Jensen et al., 2000; Xiao et al., 2003) . Previous studies have suggested that G 2 cells sense the presence of entangled and/or catenated chromatids and actively delay mitosis until decatenation is sufficiently advanced to permit mitotic cell division (Downes et al., 1994) . Therefore, conditions that slow the rate of chromatid decatenation should reduce the rate of mitotic entry by causing a G 2 delay, leading to an increase in the G 2 cell fraction.
To test this hypothesis, fibroblasts were electroporated with NTC or topoIIa siRNA and analyzed for their ability to arrest in G 2 and exit mitosis on DNA damage (ionizing radiation (IR)) or catalytic inhibition (ICRF-193) of topoII enzyme. Representative flow cytometry plots of NHF1-hTERTs are shown in Figure 4a . In both NTC and topoIIa-depleted fibroblasts, ionizing radiation produced a 75-80% average reduction in mitotic index 2 h after treatment ( Figure 4b ). This reduction of the mitotic index has previously been thought to reflect both an arrest of G 2 cells and the exit of mitotic cells into interphase after irradiation. The NTC-depleted fibroblasts retained a functional decatenation G 2 checkpoint; they displayed a mean 60% reduction in mitotic index on ICRF-193 treatment. In contrast, topoIIa-depleted fibroblasts ICRF-193 did not produce any detectable gH2AX staining until 6 h after treatment, and the signal was variable among the different NHDF lines. NHF3-hTERT cells produced substantially more gH2AX staining than the other two fibroblast lines and showed higher background levels of gH2AX. Results are presented as an average of three different NHDF cell lines±s.e.m. *Po0.05.
displayed a mean 257% increase in mitotic index on treatment with ICRF-193. These results suggested that while topoIIa depletion did not significantly alter the DNA damage-G 2 checkpoint response, it ablated the decatenation G 2 checkpoint response.
One explanation for the increase in topoIIa-depleted mitotic cells after ICRF-193 treatment was that NHDFs were delaying mitotic exit because of the persistence of centromeric DNA catenations (Diaz-Martinez et al., 2006; Santamaria et al., 2007; Coelho et al., 2008; Wang et al., 2008) . This effect might be enhanced on further inhibition of residual topoIIa and topoIIb with ICRF-193, thus prolonging the amount of time spent in mitosis. If the amount of time NHDFs spent in mitosis was altered by a decrease in topoIIa activity, it was necessary to monitor the G 2 /M transition by examining the mitotic entry rate (MER) of NHDFs in order to discriminate between the G 2 /M and spindle assembly checkpoint mechanisms. NHDFs were collected over time in colcemid, a microtubule polymerization inhibitor that arrests cells with an intact spindle assembly checkpoint at metaphase. This assay allows for a strict examination of the G 2 to M transition, and calculation of the MER by linear regression provides a quantitative measure of decatenation G 2 checkpoint function.
NTC-, topoIIa-, and topoIIb-depleted fibroblast lines displayed an increase in the percentage of mitotic cells over time in the presence of DMSO and colcemid (Figure 4c, Supplementary Figure S3 ). In contrast, when topoII activity was inhibited with ICRF-193 in NTC-or topoIIb-depleted fibroblasts, MERs were approximately zero. Surprisingly, the topoIIa-depleted fibroblasts continued to enter mitosis, regardless of the presence of ICRF-193. Comparison of MERs indicated that topoIIa-depleted cells entered mitosis at a rate that was approximately half that of NTC-treated fibroblasts (Figure 4d ). Mitotic entry in the topoIIa-depleted NHF1-hTERTs was independently verified by timelapse bright-field microscopy and full-length videos can be viewed at the laboratory's website (http://top2a. med.unc.edu/jackie/home.html). Quantification of G 2 fractions in this assay also revealed that a significant G 2 accumulation occurred on topoIIa depletion or catalytic inhibition (Supplementary Figure S4) .
Several attempts to correct the phenotype of NHDFs by over-expressing a siRNA-resistant form of topoIIa were unsuccessful because of the toxicity of topoIIa overexpression. Therefore, a second siRNA directed towards topoIIa was tested in the mitotic entry assay. The results confirmed that the observed phenotype was not because of the off-target effects of either siRNA (Supplementary Figure S5 ). Taken together, these data suggest that a catalytically inactive topoIIa protein is required to arrest cells in G 2 during incubation with ICRF-193 and prevent mitotic entry in the presence of entangled/catenated chromosomes. Furthermore, these results indicate that the decatenation G 2 checkpoint does not sense DNA catenations per se, but rather senses the catalytically inactive form of topoIIa.
TopoIIa depletion does not affect the ability of NHDFs to synthesize DNA As topoIIa protein expression is cell cycle-dependent and an earlier report suggested that type II topoisomerases are required for the completion of S phase in budding yeast (Baxter and Diffley, 2008) , it was important to determine whether topoIIa has a role in DNA synthesis and/or the completion of S phase in NHDFs. If DNA replication or completion of S phase were impaired, this could slow down the MERs. Flow cytometry was utilized to determine the capacity of topoIIa-depleted cells to incorporate the thymidine analog bromodeoxyuridine during S phase and representative flow cytometry profiles are shown (Figure 5a ). While topoIIa-depleted cells displayed normal levels of bromodeoxyuridine incorporation, there were slightly fewer fibroblasts present in S phase when compared with NTC-treated fibroblasts (Figure 5b) . This difference was determined to be insignificant by Student's t-test. However, the percentage of G 2 cells increased in topoIIa-depleted fibroblasts, suggesting that cells were indeed progressing through S phase and into G 2 phase. Similar results were obtained on ICRF-193 treatment (Supplementary Figure S6 ) and by using synchronized fibroblasts (not shown), suggesting that topoIIa depletion or inhibition does not interfere with DNA replication or completion of S phase in NHDFs. In addition, recently published data from our laboratory has suggested that neither ATR nor Chk1 depletion affected the MERs or decatenation G 2 checkpoint function of NHDFs (Bower et al., 2010) . Similarly, no Chk1 activation was observed in response to ICRF-193 treatment. These data further support the conclusion that topoII catalytic inhibition or depletion does not induce a replicative stress response in NHDFs.
TopoIIa-depleted fibroblasts display abnormal metaphase chromosome structure Inhibition of topoII with ICRF-193 produces characteristic chromosomal abnormalities in cells that evade the decatenation G 2 checkpoint. Metaphase preparations of ICRF-193-treated cells often display undercondensed and entangled chromosomes (Deming et al., 2002) . As the results in Figures 1b and 4c indicated that NHDFs enter mitosis in the absence of significant topoIIa activity, cytogenetic studies were performed to examine chromosome morphology. TopoIIa-depletion significantly increased the frequencies of metaphase preparations with under-condensed or entangled chromosomes, whereas topoIIb-depleted fibroblasts displayed no significant increase in chromosomal aberrations (Figures 6a and b) . Thus, depletion of topoIIa produced similar effects on chromosome structure as catalytic inhibition of topoII with ICRF-193.
Depletion of topoIIa increases the frequency of abnormal interphase nuclei and promotes losses and gains of the p16 INK4A tumor suppressor allele Although the cytogenetic experiments in Figures 6a and b established that NHDFs would enter mitosis with entangled chromosomes, it was unclear whether these cells would exit mitosis, re-enter interphase, and potentially duplicate a set of damaged or aneuploid chromosomes during subsequent rounds of DNA replication and cell division. As entangled chromosomes may not segregate properly at anaphase, failures of segregation (non-disjunction) can generate anaphase bridges, lagging chromosomes and/or chromosomal breakage. After restitution of interphase nuclear structure, thin bridges connecting two nuclei may be apparent or one nucleus may have two lobes. Laggard or broken chromosomes are often manifested as Figure 6c ). While NTCtreated fibroblasts showed a low frequency of nuclear abnormalities (o5%), the frequencies of abnormalities were increased to B33 or B14% after depletion of topoIIa or topoIIb, respectively (Figure 6d ). These results suggested that NHDFs could exit mitosis with chromosomal mis-segregation and/or non-disjunction errors.
Abnormal chromosome segregation can lead to the loss and gain of genetic material and promote gross chromosomal rearrangements, thereby generating chromosomal instability (reviewed in Holland and Cleveland, 2009 ). To determine whether decreased topoIIa levels and/or activity could generate genomic instability in NHDFs, fluorescence in situ hybridization probes directed towards the tumor suppressor p16 INK4A genetic locus (red) and the centromere of chromosome 9 (green) were hybridized to cytogenetic preparations (Figure 7a ). NHDFs with 2-4 copies of each locus were considered to retain a normal allelic copy number to account for DNA replication in the log phase cells. At least 100 interphase cells were analyzed from each NHDF line. The topoIIb-depleted fibroblasts failed to show any significant allelic copy number changes when compared with NTC-treated fibroblasts (Figure 7b ). However, the topoIIa-depleted NHDFs displayed increased frequencies of gains and deletions of the p16 INK4A allele. These results indicate that topoIIa is required for proper chromatid segregation during mitosis, and that decreased topoIIa levels and/or activity may generate or enhance the losses/gains of the tumor suppressor p16 INK4A genetic locus. Collectively, these results suggest that topoIIa is required to maintain a barrier against tumor initiation and/or progression.
Owing to the large increase in the number of abnormal interphase nuclei and the changes in the copy number of the p16 INK4A genetic locus after depletion in topoIIa level, topoIIa-depleted NHDFs were examined for their ability to undergo clonal expansion. A clonogenic survival assay was performed in NHDFs after transient topoIIa depletion (Figure 7c) . These results confirm that topoIIa is an essential gene with transient depletion of the protein reducing colony formation by an average of 68%. The colonies that escaped clonal inactivation after depletion of topoIIa may have arisen from cells that recovered topoIIa expression before lethality was manifested.
Discussion
The decatenation G 2 checkpoint was originally proposed to delay entry into mitosis when chromosomes were insufficiently decatenated by topoII. Earlier evidence for this checkpoint was largely derived from pharmacological analyses using topoII catalytic inhibitors, such as ICRF-193 (Downes et al., 1994; Deming et al., 2001) . This study provides biological evidence for the existence of a decatenation G 2 checkpoint that is molecularly distinct from the DNA damage-G 2 checkpoint in three genetically diverse NHDFs (Figures 3 and  4) . The earlier studies in which ICRF-193 triggered a DNA damage response in some cancer lines could have used cell lines with a lax decatenation G 2 checkpoint response, such as some HeLa cell lines (Bower JJ and Kaufmann WK, unpublished data) . HeLa cells would therefore enter mitosis in the presence of catenated chromosomes, acquire DSBs on mitotic exit, and thus trigger a gH2AX and DNA damage response. TopoIIa-depleted mitotic cells displayed high frequencies of entangled and under-condensed chromosomes (Figures 6a and b ) similar to biological effects recognized in cells treated with ICRF-193 that escape the decatenation G 2 checkpoint. Abnormal nuclear structures that arise on the failure of chromatid decatenation and subsequent mal-segregation were also observed in topoIIa-depleted fibroblasts (Figures 6c and  d) , suggesting that the decatenation G 2 checkpoint is required to prevent the breakage of sister chromatids during the metaphase/anaphase transition. Furthermore, ICRF-193 treatment failed to prevent mitotic entry in topoIIa-depleted cells, indicating that the topoIIa protein has an important role during the G 2 /M transition. NHDFs that enter mitosis in the absence of topoIIa, and thus escape decatenation G 2 checkpoint activation, displayed losses and gains of the p16 INK4A tumor suppressor gene. Collectively, these observations suggest that attenuation of the decatenation G 2 checkpoint is one mechanism by which genomic instability may be generated, leading to tumor initiation and/or progression.
Although topoIIa and topoIIb have similar in vitro biochemical activities, the results herein imply that the physiological roles of these proteins are very different. This is not unexpected, given that earlier studies have suggested an independent role for topoIIb in repairing DNA cross-links and DSB-induced transcription factor recruitment (Emmons et al., 2006; Ju et al., 2006) . Furthermore, the data above suggest that topoIIb activity is sufficient for S phase progression in NHDFs, but insufficient for decatenation G 2 checkpoint activation (Figures 4 and 5) .
Our results are comparable to other studies in that topoIIa appears to be required for condensation and segregation of daughter chromosomes, with little contribution by topoIIb to this process. Targeted disruption of the TOP2A gene in the HT1080 fibrosarcoma line, siRNA depletion of topoIIa in HeLa cells, and DT40 conditional topoIIa-depleted avian B-cells produced similar results (Carpenter and Porter, 2004; Li et al., 2008; Johnson et al., 2009) . Recent reports also suggest that topoIIa may interact with mediator of DNA damage checkpoint protein 1 (MDC1) to enforce the decatenation G 2 checkpoint (Luo et al., 2009) , and that topoIIa can be SUMOylated to assist in centromere localization and proper chromosome segregation (Diaz-Martinez et al., 2006; Dawlaty et al., 2008) . However, none of these studies have addressed the role of the decatenation G 2 checkpoint in genomic stability.
As many dietary components are known topoII catalytic inhibitors/poisons Osheroff, 2007, 2008; Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2007) , it is possible that successive rounds of bypassing the decatenation G 2 checkpoint could be an important consideration for the study of tumor initiation and progression. As TOP2A allelic deletions have been observed in breast cancer patients, exposure to these dietary compounds may increase genomic instability in these cancers and accelerate tumor progression (Beser et al., 2007) . A further understanding of the signaling mechanisms involved in the decatenation G 2 checkpoint could potentially lead to the identification of early stage biomarkers and new therapeutic targets for a subset of cancers.
Materials and methods
Experimental design and cell culture NHDFs were described previously (Simpson et al., 2005) . Each fibroblast line was isolated from a different individual and underwent o100 population doublings. Experiments were performed in all three NHDF lines to assess biological reproducibility and inter-individual genetic variation. NHDFs were grown in Dulbecco's modified Eagle medium/10% fetal bovine serum/2 mM L-glutamine and maintained at 5% CO 2 and 37 1C. Periodic tests for mycoplasma contamination using a commercial kit (Gen-Probe, San Diego, CA, USA) were negative.
In vitro decatenation assay 10 7 fibroblasts were fractionated with a ProtoJET Nuclear Extraction Kit (Fermentas, Glen Burnie, MD, USA). Nuclear extracts were assayed for decatenatory activity using the TopoGEN Eukaryotic TopoII Assay kit (TopoGEN, Port Orange, FL, USA). kDNA was electrophoresed in a 1% agarose gel to separate topoisomers, stained with SYBR Gold (Invitrogen, Carlsbad, CA, USA), analyzed using a Typhoon 9400 (GE Healthcare, Piscataway, NJ, USA), and quantified by ImageQuant TL version 2005 Software (GE Healthcare).
Time-lapse microscopy
The NHDFs were treated with 0.1% DMSO or 4 mM ICRF-193 (Sigma, St Louis, MO, USA) at time 0. Bright-field timelapse images were captured every 2 min at the Michael Hooker Microscopy Facility and the Microscopy Services Laboratory Core Facility at UNC-CH.
Immunofluorescence and gH2AX flow cytometry
The NHDFs plated on coverslips were treated for 0, 0.25, 2 or 6 h with 4-12 mM Etoposide, 4 mM ICRF-193 or 0.1% DMSO. Coverslips were removed and fixed with 95% ethanol: 5% acetic acid. The remaining cells were analyzed by flow cytometry. Samples were stained with a Phospho-Ser139 H2AX antibody (Millipore, Billerica, MA, USA) and an anti-mouse Texas Red secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole. Images were obtained on a Leica DMIRB inverted fluorescence microscope at the Michael Hooker Microscopy Facility . Flow cytometry samples were measured on a Dako CyAN ADP instrument at the Flow Cytometry Core Facility at UNC-CH and plots were analyzed using Summit 4.3 software. Percentages of gH2AX positive cells were plotted against time and linear regression slopes were calculated for each treatment group. Statistical analysis was performed using a Student's t-test.
Ionizing radiation
A gamma cell 40 Cs 137 irradiation source was used for ionizing radiation treatment. Mitotic index was determined by the flow cytometry protocol described below 2 h after irradiation.
Electroporation of fibroblasts
The NTC (5 0 -UGGUUUACAU GUCGACUAA-3 0 ), topoIIa (5 0 -CUGCCUGUUUAGUCGCUUUC A-3 0 ), and topoIIb (5 0 -GAAGUUGUCUGUUGAGAGAUU-3 0 ) siRNA were obtained from Dharmacon (Dharmacon, Lafayette, CO, USA). A second topoIIa siRNA was obtained from Invitrogen (5 0 -GAGAUGUCACUAAUGAUGACCAUUA-3 0 ). The NHDFs were electroporated using an NHDF Nucleofector Kit (Lonza, Basel, Switzerland), and assayed for biological effects 48 h post-electroporation. Protein depletion for each individual experiment was confirmed by western immunoblot at time of assay.
Western immunoblot
Standard immunoblotting techniques were used to detect expression of topoIIa and topoIIb. Briefly, equal amounts of total cellular protein were electrophoresed on 7% SDS-PAGE gels, transferred to nitrocellulose membranes and blocked in 4% bovine serum albumin/tris-buffered saline with tween-20 . TopoIIa and topoII b antibodies were obtained from BD Biosciences (San Jose, CA, USA). Secondary anti-mouse Cy3/ Cy5 antibodies were obtained from GE Healthcare and fluorescence was measured on a Typhoon 9400. Quantification of protein expression was performed using ImageQuant TL.
Flow cytometric mitotic entry assay Electroporated fibroblasts were plated at a density of 10 6 cells (day 0), and fed with fresh medium on day 1. On day 2, cells were treated with 100 ng/ml colcemid and either 0.1% DMSO or 4 mM ICRF-193 for 2, 4 and 6 h. Fibroblasts were fixed with 95% ethanol: 5% acetic acid. A phospho-Ser10 histone H3 primary antibody (Millipore) and a fluorescein isothiocyanatelabeled secondary (Santa Cruz Biotechnology) were used to identify mitotic cells. Propidium iodide was used to measure DNA content. Summit 4.3 plots were used to quantify the percentage of NHDFs with 4N DNA content and phospho-Ser10 histone H3. The percentage of mitotic cells for each sample was plotted against time and the resulting slope of the line was used to measure the MER (% entering mitosis/hour).
Flow cytometry bromodeoxyuridine incorporation
Fibroblasts were incubated with 10 mM bromodeoxyuridine for 2 h and fixed with 70% ethanol. An anti-bromodeoxyuridinefluorescein isothiocyanate antibody (BD Biosciences) was used to identify cells with actively replicating DNA. Propidium iodide was used to measure DNA content. Summit 4.3 plots were used to quantify the percentage of fibroblasts in G 0 /G 1 , S and G 2 /M phase.
Cytogenetic studies
Fibroblasts were incubated with 100 ng/ml colcemid for 1 h, incubated in hypotonic KCl (75 mM), and fixed with 3:1 methanol:acetic acid. Nuclei were dropped onto microscope slides and Geimsa-stained for visualization (Kaufmann et al., 1997) . Metaphases were examined using an Olympus BH2 microscope with a SPOT RT camera (Olympus, Center Valley, PA, USA). 50 þ metaphases were scored for each treatment group/cell line. All analyses were performed blinded to sample identity.
Nuclear abnormality assessment
The NHF1-hTERT cells were electroporated with siRNA as described above and allowed to adhere to coverslips. After 48 h, the coverslips were fixed with 3:1 methanol:acetic acid and stained with 4 0 ,6-diamidino-2-phenylindole. Coverslips were mounted onto slides and 1000 þ interphase nuclei were analyzed in a blind manner for structural abnormalities (blebs, bridges, and micronuclei) at the Michael Hooker Microscopy Facility .
Fluorescence in situ hybridization (FISH) A second set of cytogenetic metaphase preparations were artificially aged in 2 Â saline-sodium citrate /0.1% Nonidet P-40 (NP-40) for 30 min at 37 1C, successively dehydrated in 70, 85 and 100% ethanol, and air-dried. A Vysis LSI p16 (9p21) Spectrum Orange/CEP9 Spectrum Green probe (Abbott Molecular, Des Plaines, IL, USA) was hybridized to metaphase preparations overnight using a Vysis HyBrite (Abbott Diagnostics, Abbott Park, IL, USA) according to the probe manufacturer's instructions. Gene copy numbers were assessed in a blind manner for both the p16 INK4A locus and the CEP9 locus for at least 100 interphase nuclei per sample.
Clonogenic survival assay
Single cell suspensions of fibroblasts were electroporated with NTC, topoIIa-or topoIIb-directed siRNA as described. One thousand cells were plated in triplicate. Colonies were fed every 2-3 days with fresh medium and stained for14 days after electroporation with 0.05% crystal violet/40% methanol. Colonies with 450 cells were counted (Zhou et al., 2006) .
